A Cochrane Review of anti-IL-5 (Mepolizumab) and anti-IL-5R (Benralizumab) in the treatment of COPD, demonstrating some evidence of potential benefits in select subgroups but not broad efficacy [60]. Here, IL5 is linked to chronic obstructive pulmonary disease.